Clinical trials are complex undertakings and whether by necessity or strategic design, an increasing number of trials are now outsourced by pharma and biotech firms. This often requires the use of multiple partners to complete all aspects of a clinical trial. Greg Guarasci (Senior Vice President, Operations and General Partner) is joined by Lara Longpre of Jennerex Biotherapeutics to consider if these multiple partnerships are the way of the future,
Ask the Experts: Why Do Rare Disease Clinical Trials Require a Unique Approach?
According to the National Organization for Rare Disorders (NORD), 90% of rare disorders do not have an FDA-approved treatment. We spoke with Juliane…
Master Protocols in Clinical Trials
Master protocols are a powerful but under-utilized option for complex clinical development programs. Our Greg Licholai, MD, explores:
Strong Site Selection Leads To Success
A randomized, double-blind, placebo-controlled Phase III study of Study Drug versus placebo for patients with advanced gastrointestinal stromal…